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PERIPHERAL ARTERY DISEASE
Peripheral artery disease (PAD) is defined as a narrowing 
of arteries that are neither cardiac nor intracranial. It is a 
growing public health concern affecting 8.5 million people 
in the United States and 200 million people worldwide 
(Kullo and Rooke, 2016). The major mechanism of PAD is 
atherosclerosis, a disease in which plaque accumulates 
inside the arterial intima. Plaque accumulation obstructs the 
lumen of the vessel causing a reduction in blood flow, which 
leads to diminished oxygen supply to the recipient tissues. 
Certain natural branch points and curvatures within the vas-
cular tree are more susceptible to atherosclerosis due to tur-
bulent blood flow and shear stress. Current understanding 
suggests that turbulent blood flow at very low shear stress 
compromises the integrity of the endothelial lining. Such 
hemodynamic changes appear to be linked to the devel-
opment of focal atherosclerosis (Davies et al., 1986). Areas 
known to be frequently affected include the aorta, as well as 
the coronary and carotid arteries (VanderLaan et al., 2003). 
Other causes of PAD include inflammatory vasculitis and 
non-inflammatory arteriopathies (Kullo and Rooke, 2016). 
The main risk factors for developing PAD are diabetes mel-
litus and smoking (Kullo and Rooke, 2016). The incidence 
of PAD increases with age; 20% of people over 60 years 
old have some degree of PAD (National Clinical Guideline 
Centre, 2012).
Symptomatic presentation of PAD ranges from leg discom-
fort and pain at rest, to intermittent claudication, to critical 
limb ischemia resulting in gangrene and subsequent ampu-
tation (Kullo and Rooke, 2016). Other signs of PAD include 
differences in color and/or temperature of the lower limbs 
compared with other body parts, as well as pallor on eleva-
tion of the lower limb above 60º (Swartz, M. H. 2006).
Diagnosis of PAD typically occurs after symptoms are 
reported and a thorough physical examination has been 
performed. Diagnostic tests include the ankle-brachial index 
(ABI) test, Doppler ultrasound, the treadmill test, magnetic 
resonance angiogram, and arteriogram (National Heart, 
Lung, and Blood Institute, 2015). Upon diagnosis, PAD can 
be categorized using a number of classification systems. One 
of the most common, and the most relevant to lower limb 
ischemia, is the Rutherford classification system (Hardman 
et al., 2014). This scheme, developed in 1986, distinguishes 
between PAD-related chronic and acute limb ischemia. 
The chronic classification system relies on a combination of 
objective criteria (e.g. ABI) and symptomatic description in 
determining the classification of PAD. Symptomatic descrip-
tions range from asymptomatic, to increased claudication, 
to tissue loss (Hardman et al., 2014).
The ABI is the relationship between systolic blood pressure 
in the ankle and systolic blood pressure in the arm. The 
normal range is 1.00–1.30. An ABI under 0.90 is indicative 
of PAD (Kullo and Rooke, 2016). A low ABI suggests that 
the systolic blood pressure is lower in the legs than in the 
arms, which indicates possible arterial blockage. The ABI, 
ultrasound imaging, and treadmill tests are all non-invasive 
methods of diagnosis.
The objectives of PAD management are to alleviate symp-
toms, to reduce the risk of adverse cardiovascular events, 
and to preserve limb function. Smoking cessation, dietary 
modifications, and other healthy lifestyle changes can 
improve patient outcomes. Surgical revascularization is 
required when behavioral modifications are not effective. 
Often, the initial treatment approach is balloon angioplasty 
with or without stenting to widen the arterial lumen and 
improve blood flow (Slovut and Lipsitz, 2012). When an 
endovascular approach is not feasible, open surgical inter-
vention is necessary to restore adequate blood flow to the 
lower limbs. The three main open surgical procedures are 
aortofemoral bypass grafting (AOFBG), axillofemoral bypass 
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mulates in the arterial system and obstructs blood flow. 
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Surgical revascularization is the primary mode of treat-
ment for patients with severe limb ischemia. The objec-
tive of the surgical procedure is to bypass a blockage in 
an occluded major vessel by constructing an alternate 
route for blood flow using an artificial graft. This article 
presents information on aortoiliac reconstruction, with an 
emphasis on axillobifemoral bypass grafting.
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grafting (AXFBG), and aortoiliac endarterectomy (Slovut 
and Lipsitz, 2012). AOFBG is classified as an anatomic pro-
cedure, meaning that the graft is constructed alongside the 
diseased artery using a transabdominal or retroperitoneal 
approach. AXFBG is classified as extra-anatomic because 
the graft is placed subcutaneously and, therefore, does not 
have spatial relation to the diseased artery throughout most 
of its length (Slovut and Lipsitz, 2012). Graft configuration 
is determined based on the location of the occlusion and 
surgical risk of the individual patient. Figure 1 demonstrates 
several bypass configurations. The present article focuses 
on the history and surgical techniques of the AXFBG bypass 
and refers to Matakas et al. (2016), a reflection presented in 
this issue on the discovery of an AXbiFBG upon cadaveric 
dissection. 
HISTORICAL CONTEXT AND SURGICAL TECHNIQUE OF 
AXILLOFEMORAL BYPASS
Prior to the development of the AXFBG, other arterial 
graft procedures were used to restore adequate blood 
flow around an area of obstruction. For example, in 1953, 
Freeman and Leeds published an article describing how 
the splenic artery was used to bypass the abdominal aorta. 
In 1960, cross-over grafts were described between the 
common iliac arteries (McCaughan and Kahn, 1960), and in 
1961, thoracic aorta to femoral artery bypass grafts were 
described (Blaisdell et al., 1961). These procedures were 
successful in patients with unilateral occlusion; however, 
they were of limited use for patients with high surgical risk, 
or those with bilateral occlusion. In 1963, Blaisdell and Hall 
reported that they successfully performed the first AXFBG. 
In fact, they performed the procedure on three patients who 
presented with high surgical risk and bilateral occlusive dis-
ease. In one of the patients, AXFBG was performed using 
only local anesthesia, highlighting the utility of AXFBG in 
patients who could not tolerate general anesthesia. Further, 
AXFBG provided a major advantage over other procedures 
by avoiding abdominal incision and cross-clamping of the 
aorta, both of which entail significant physiologic stress to 
the patient (Blaisdell and Hall, 1963; Al Wahbi, 2010). 
In 1966, Sauvage and Wood adapted the AXFBG procedure 
to accommodate bilateral occlusions and performed the 
first axillobifemoral bypass graft (AXbiFBG). In the original 
configuration of these grafts, the bifurcation was placed at 
the level of the umbilicus (Figure 1D). The flow rates differed 
to the ipsilateral and contralateral limbs, which affected the 
patency of these early grafts (Ray et al., 1979). Subsequently, 
the configuration was changed so that the bifurcation 
occurred at the femoral hood of the graft (Ray et al., 1979), 
and this configuration continues to be used today.
Early AXbiFBG grafts were made of crimped, non-supported 
Dacron®, but problems arose with thromboses due to com-
pression of the graft during sleep (Kenney et al., 1982). 
Kenney later demonstrated that the use of non-crimped 
grafts with external support improved the graft’s four-year 
patency rate because they were incompressible (Kenney 
et al., 1982). Burrell et al. (1982) compared the effective-
ness of Dacron® versus polytetrafluoroethylene (PTFE) on 
graft patency, and found no significant difference in patency 
rates. These conclusions were replicated and confirmed by 
Donaldson et al., in 1986. 
Other attempts to prevent clot formation in grafts included 
bonding various agents to the internal surface of the graft 
material. Some of the agents used were gelatin, collagen, 
and heparin (Roll et al., 2008; Takagi et al., 2010). It is 
unclear whether these enhanced grafts had any effect on 
overall patency rates, as there is limited literature available 
comparing the functionality of different bonding agents.
The AXbiFBG procedure has been described in the litera-
ture several times with slight variations related to the sur-
geon’s preference (Blaisdell and Hall, 1963; Sauvage and 
Wood, 1966; Mannick and Nabseth, 1968; Al-Wahbi, 2010; 
Figure 1 | Aortoiliac reconstruction bypass configurations. A. Normal arterial configuration. B. Aortoiliac graft for 
inferior mesenteric and common iliac blockage. C. Aortoiliac graft for external iliac blockage. D. Axillobifemoral 
graft (early version). E. Axillobifemoral graft (current version).
Normal
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Figure 2 | Axillobifemoral bypass (AXbiFBG) procedure. Illustrated is the axillary anastomosis (top left), femoral anastomosis (top right), and 
general configuration (bottom). (After Mannick, J. A., and Nabseth D. C. (1968)). 
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Slovut and Lipsitz, 2012; Jun and Lopez, 2015). The proce-
dure is typically performed with the patient under general 
anesthesia, but can be performed with local anesthetic, with 
or without sedation, according to the needs of the patient 
(Al-Wahbi, 2010).
A schematic for placing the AXbiFBG is depicted in Figure 2. 
Proximally, a horizontal incision is made just below the clav-
icle and a small portion (2.5–5 cm) of the proximal axillary 
artery is freed from the surrounding tissues. The pectoralis 
major and/or minor muscles are split to facilitate this dissec-
tion. Distally, just below the ipsilateral inguinal ligament, a 
vertical incision is made and the femoral sheath is entered. 
The common femoral artery is freed and inspected, along 
with the superficial and profunda femoral arteries. These 
arteries are evaluated for disease and local endarterectomy 
is performed if necessary. If placement of a bifemoral shunt 
is required, the same inguinal technique is repeated on the 
contralateral side to access and assess that femoral artery 
(Sauvage and Wood, 1966).
With the proximal (axillary) and distal (femoral) arteries 
exposed, a subcutaneous tunnel is made along the midaxil-
lary line, connecting the two arteries. When a bifemoral graft 
is needed, a horizontal tunnel is prepared connecting the 
two common femoral arteries. The graft is carefully passed 
through the tunnel and longitudinal arteriotomies are per-
formed to anastomose the graft and the artery (Blaisdell 
and Hall, 1963). While premade AXbiFBGs are now avail-
able, the bifemoral portion can also be anastomosed to an 
AXFBG (Jun and Lopez, 2015).
Pre-operative considerations for AXFBG include assessment 
of the axillary arteries to ensure there is no stenosis or other 
disease. Resting ankle-brachial pressure indices are taken 
and the patient’s surgical risk is assessed. Those patients 
who have high surgical risk due to prior abdominal sur-
geries, age, or other health conditions that would preclude 
them from an anatomic bypass (AOFBG), are frequently 
able to withstand AXFBG. 
Complications of AXFBG include graft thrombosis or infec-
tion (Passman et al., 1996; Ray et al., 1979; Burrell et al., 
1982; Donaldson et al., 1986), seroma (Donaldson et al., 
1986), plexus lesions (Kempczinski and Penn, 1978), and 
arterial steal syndrome (Kempczinski and Penn, 1978). 
Patients may need to undergo a thrombectomy or total graft 
replacement in order to maintain patency. Complications are 
most likely to occur within the first 36 months following sur-
gery, with the average being 21.5 months (Donaldson et. al., 
1986). In some cases, if the graft cannot be fixed, patients 
will undergo amputation (Donaldson et al., 1986). Due to 
the possibility of developing these severe complications, 
some have called into question the usefulness of AXFBG 
(Donaldson et al., 1986). Despite the complication rate, the 
five-year primary graft patency rate has been reported in the 
range of 54% (Martin and Katz, 2000) to 80.4% (Passman et 
al., 1996; Ray et al., 1979). In patients that undergo throm-
bectomy, as many as 97% can expect no further complica-
tions over the following five-year period (Burrell et al., 1982).
Post-operative care for AXFBG patients may include the 
use of anti-thrombotic agents, particularly in patients who 
require multiple reoperations to maintain graft patency 
(Donaldson et al., 1986). Some evidence has shown that 
anti-platelet medications such as aspirin can be beneficial 
for patients with synthetic grafts (Slovut and Lipsitz, 2012; 
Dorffler-Melly et al., 2003). The use of warfarin, however, 
has been associated with an increased risk of hemorrhage 
(Slovut and Lipsitz, 2012). Patients should be routinely 
monitored for recurrence of symptoms, which indicates the 
development of thrombosis (Slovut and Lipsitz, 2012).
SUMMARY
PAD can be managed using multiple modalities. However, 
in people with severe disease, surgical bypass grafts are the 
standard of care. This report discusses the history and sur-
gical techniques of the extra-anatomic procedures known as 
AXFBG and AXbiFBG. Both the literature and the evidence 
from the case report (Matakas et al., 2016) support the utility 
of axillobifemoral bypass graft in restoring adequate blood 
flow to the lower limbs. The first-year medical students who 
discovered an AXbiFBG in their anatomy cadaver were so 
curious about the graft, and the disease that it was used to 
treat, that they were inspired to learn more and, ultimately, 
to share what they learned with others.
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